The p23 co-chaperone is a succinate-activated COX-2 transcription factor in lung adenocarcinoma tumorigenesis.


Journal

Science advances
ISSN: 2375-2548
Titre abrégé: Sci Adv
Pays: United States
ID NLM: 101653440

Informations de publication

Date de publication:
30 06 2023
Historique:
medline: 3 7 2023
pubmed: 30 6 2023
entrez: 30 6 2023
Statut: ppublish

Résumé

P23, historically known as a heat shock protein 90 (HSP90) co-chaperone, exerts some of its critical functions in an HSP90-independent manner, particularly when it translocates into the nucleus. The molecular nature underlying how this HSP90-independent p23 function is achieved remains as a biological mystery. Here, we found that p23 is a previously unidentified transcription factor of COX-2, and its nuclear localization predicts the poor clinical outcomes. Intratumor succinate promotes p23 succinylation at K7, K33, and K79, which drives its nuclear translocation for COX-2 transcription and consequently fascinates tumor growth. We then identified M16 as a potent p23 succinylation inhibitor from 1.6 million compounds through a combined virtual and biological screening. M16 inhibited p23 succinylation and nuclear translocation, attenuated COX-2 transcription in a p23-dependent manner, and markedly suppressed tumor growth. Therefore, our study defines p23 as a succinate-activated transcription factor in tumor progression and provides a rationale for inhibiting p23 succinylation as an anticancer chemotherapy.

Identifiants

pubmed: 37390202
doi: 10.1126/sciadv.ade0387
pmc: PMC10313168
doi:

Substances chimiques

Succinic Acid AB6MNQ6J6L
Transcription Factors 0
Cyclooxygenase 2 EC 1.14.99.1
Pyridinolcarbamate 81R511UV73
Succinates 0
Molecular Chaperones 0
HSP90 Heat-Shock Proteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

eade0387

Références

Cell Death Dis. 2019 Feb 20;10(3):170
pubmed: 30787272
Trends Cell Biol. 2014 Aug;24(8):455-63
pubmed: 24731398
PLoS One. 2018 Dec 18;13(12):e0208955
pubmed: 30562372
J Natl Cancer Inst. 2017 Jan 25;109(6):
pubmed: 28122908
Environ Sci Pollut Res Int. 2019 Feb;26(6):6014-6022
pubmed: 30613888
Biochemistry. 2018 Feb 13;57(6):935-944
pubmed: 29334217
Stem Cells Int. 2016;2016:2048731
pubmed: 27882058
Nat Cell Biol. 2015 Oct;17(10):1317-26
pubmed: 26302408
J Biol Chem. 2000 Jul 28;275(30):23045-52
pubmed: 10811660
Mol Cell. 2020 Jan 16;77(2):213-227.e5
pubmed: 31735641
J Comput Chem. 2005 Dec;26(16):1668-88
pubmed: 16200636
J Clin Invest. 2007 May;117(5):1175-83
pubmed: 17476347
Biomed Pharmacother. 2018 Jun;102:221-229
pubmed: 29562216
J Biol Chem. 2006 May 19;281(20):14457-64
pubmed: 16565516
Mol Oncol. 2015 Jan;9(1):295-308
pubmed: 25241147
Biochem Pharmacol. 2018 Jun;152:34-44
pubmed: 29555469
Nature. 2013 Apr 11;496(7444):238-42
pubmed: 23535595
Basic Clin Pharmacol Toxicol. 2013 Apr;112(4):270-81
pubmed: 23061789
Biosci Rep. 2012 Feb;32(1):1-15
pubmed: 21981137
Oncogene. 2014 May 15;33(20):2547-56
pubmed: 23812428
Oncotarget. 2018 Jan 3;9(9):8415-8426
pubmed: 29492204
Mol Cell. 2011 Jul 22;43(2):229-41
pubmed: 21777812
Proc Natl Acad Sci U S A. 2011 Jan 11;108(2):580-5
pubmed: 21183720
Mol Cell Endocrinol. 2018 Jul 5;469:107-111
pubmed: 28739378
Leuk Res. 2012 Sep;36(9):1098-104
pubmed: 22677230
Nat Chem Biol. 2011 Jan;7(1):58-63
pubmed: 21151122
Mol Cancer. 2014 Aug 31;13:203
pubmed: 25175164
Cell Physiol Biochem. 2018;47(3):1244-1258
pubmed: 29913439
Mol Cell Biol. 1998 Jul;18(7):3727-34
pubmed: 9632755
Mol Cell. 2021 Jun 3;81(11):2303-2316.e8
pubmed: 33991485
Inflamm Res. 2020 Jun;69(6):619-630
pubmed: 32328683
Curr Protoc Mol Biol. 2011 Jan;Chapter 13:Unit13.10B
pubmed: 21225637
Adv Biol Regul. 2018 May;68:39-45
pubmed: 29428221
J Cell Biochem. 2018 Aug;119(8):6492-6500
pubmed: 29345337
Mol Endocrinol. 2012 Oct;26(10):1694-706
pubmed: 22899854
Int J Immunopathol Pharmacol. 2006 Apr-Jun;19(2):409-19
pubmed: 16831307
Mol Cell. 2016 Dec 1;64(5):888-899
pubmed: 27818141
Trends Cell Biol. 2014 May;24(5):313-20
pubmed: 24361092
Nature. 2017 Dec 14;552(7684):273-277
pubmed: 29211711
Proc Natl Acad Sci U S A. 2019 Mar 19;116(12):5223-5232
pubmed: 30819896
J Cell Physiol. 2019 May;234(5):5683-5699
pubmed: 30341914
Cancer Cell Int. 2015 Nov 05;15:106
pubmed: 26549987
Semin Immunol. 2022 Jan;59:101606
pubmed: 35691882
Hum Mol Genet. 2006 Jun 1;15(11):1876-83
pubmed: 16644868
Endocr Relat Cancer. 2014 Aug;21(4):567-77
pubmed: 24859990
Semin Cell Dev Biol. 2020 Feb;98:4-14
pubmed: 31039394
Cancer Res. 2010 Nov 1;70(21):8446-56
pubmed: 20847343
Ann Afr Med. 2019 Jul-Sep;18(3):121-126
pubmed: 31417011
Toxicol Mech Methods. 2019 Oct;29(8):569-579
pubmed: 31161897
Eur Heart J. 2017 Nov 21;38(44):3282-3292
pubmed: 29020251
Genes Dev. 1999 Apr 1;13(7):817-26
pubmed: 10197982
Mol Cell Biol. 1999 May;19(5):3748-59
pubmed: 10207098
Cell Stress Chaperones. 2010 Sep;15(5):703-15
pubmed: 20349287
J Exp Clin Cancer Res. 2020 Aug 28;39(1):172
pubmed: 32859246
Int J Biochem Cell Biol. 2019 Mar;108:17-20
pubmed: 30630112
Mol Ther. 2019 Oct 2;27(10):1718-1725
pubmed: 31526596
Nat Rev Rheumatol. 2017 May;13(5):267-279
pubmed: 28331208
Cell. 2013 Mar 28;153(1):56-69
pubmed: 23540690

Auteurs

Zhenlong Yu (Z)

College of Pharmacy, the Second Affiliated Hospital, Dalian Medical University, Dalian 116000, China.

Yulin Peng (Y)

College of Pharmacy, the Second Affiliated Hospital, Dalian Medical University, Dalian 116000, China.

Jian Gao (J)

Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical University, Xuzhou 221004, China.
School of Medicine, Anhui University of Science and Technology, Huainan 232001, China.

Meirong Zhou (M)

College of Pharmacy, the Second Affiliated Hospital, Dalian Medical University, Dalian 116000, China.

Lei Shi (L)

College of Pharmacy, the Second Affiliated Hospital, Dalian Medical University, Dalian 116000, China.

Feng Zhao (F)

College of Pharmacy, the Second Affiliated Hospital, Dalian Medical University, Dalian 116000, China.

Chao Wang (C)

College of Pharmacy, the Second Affiliated Hospital, Dalian Medical University, Dalian 116000, China.

Xiangge Tian (X)

College of Pharmacy, the Second Affiliated Hospital, Dalian Medical University, Dalian 116000, China.

Lei Feng (L)

College of Pharmacy, the Second Affiliated Hospital, Dalian Medical University, Dalian 116000, China.

Xiaokui Huo (X)

College of Pharmacy, the Second Affiliated Hospital, Dalian Medical University, Dalian 116000, China.

Baojing Zhang (B)

College of Pharmacy, the Second Affiliated Hospital, Dalian Medical University, Dalian 116000, China.

Min Liu (M)

Neurology Department, Dalian University Affiliated Xinhua Hospital, Dalian 116021, China.

Deyu Fang (D)

Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.

Xiaochi Ma (X)

College of Pharmacy, the Second Affiliated Hospital, Dalian Medical University, Dalian 116000, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH